GenprexGNPX
About: Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Employees: 25
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
40% more funds holding
Funds holding: 15 [Q2] → 21 (+6) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
4.53% less ownership
Funds ownership: 12.96% [Q2] → 8.44% (-4.53%) [Q3]
88% less capital invested
Capital invested by funds: $513K [Q2] → $61.7K (-$451K) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for GNPX.